Research Article

Expression and clinical value of the soluble major histocompatibility complex class I-related chain A molecule in the serum of patients with renal tumors

Published: June 29, 2015
Genet. Mol. Res. 14 (2) : 7233-7240 DOI: https://doi.org/10.4238/2015.June.29.16
Cite this Article:
(2015). Expression and clinical value of the soluble major histocompatibility complex class I-related chain A molecule in the serum of patients with renal tumors. Genet. Mol. Res. 14(2): gmr5500. https://doi.org/10.4238/2015.June.29.16
901 views

Abstract

We investigated the expression and clinical value of the soluble major histocompatibility complex class I-related chain A (sMICA) molecule in the serum of patients with renal tumors. Sixty patients diagnosed with renal tumors were enrolled in the experimental group, whereas 20 healthy volunteers served as the control group. The sMICA levels were measured via enzyme-linked immunosorbent assay, and the results were analyzed in combination with data from pathol­ogy examination. The experimental group had a statistically significant higher sMICA level (P

We investigated the expression and clinical value of the soluble major histocompatibility complex class I-related chain A (sMICA) molecule in the serum of patients with renal tumors. Sixty patients diagnosed with renal tumors were enrolled in the experimental group, whereas 20 healthy volunteers served as the control group. The sMICA levels were measured via enzyme-linked immunosorbent assay, and the results were analyzed in combination with data from pathol­ogy examination. The experimental group had a statistically significant higher sMICA level (P